Rand Capital Corp, a traded business development company invests in lower middle market companies located in the United States with EBITDA of up to USD 5 million and minimum revenues of USD 2 million. It targets companies operating on a broad range of sectors. It provides subordinated debt with warrants or preferred equity financing for early stage, later stage and growth stage capital requirements with an investment size of USD 0.75 - 5 million. It makes co-investments and acquires minority interest.
Clinical Trials
114
6 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
4
3.5%
Completed
96
84.2%
Not yet recruiting
2
1.8%
Recruiting
5
4.4%
Terminated
3
2.6%
Unknown
2
1.8%
Withdrawn
2
1.8%
No approval data available
- A RAND study funded by California's DIR and DWC found access to medical care remained largely stable for most injured workers from 2017 through 2024. - Travel distances to receive care increased in rural and suburban areas, while provider participation was lower than expected in the Inland Empire and Los Angeles. - The report is the first of four annual studies establishing a baseline to track injured workers' access to care and the factors influencing it. - The study examined timeliness of care, provider supply, specialty differences, and telehealth adoption, particularly for behavioral health care.
- Multiple states including Texas, Mississippi, and West Virginia are advancing legislation to fund clinical trials of ibogaine, a psychedelic compound derived from the African shrub iboga, for treating PTSD and opioid addiction. - Texas has already approved $50 million for ibogaine clinical trials, while Mississippi and West Virginia have passed bills with overwhelming legislative support to establish research programs aimed at FDA approval. - A 2024 Stanford Medicine study demonstrated that ibogaine provided veterans with relief from depression, anxiety, and poor functioning symptoms, with patients typically finding relief in one treatment. - The drug is currently classified as a Schedule I controlled substance in the US, forcing patients seeking treatment to travel to countries like Mexico for care.
